Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Clinical trial register
Trackers› Clinical trials› Taiwan
Clinical trial register · Taiwan

Clinical Trials in Taiwan

Every study on the ClinicalTrials.gov registry that lists a site in Taiwan and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 2861 matching records held by the registry are in this view. Synced 15 Nov 2026, 03:18 UTC
2861
Studies in scope
all four open statuses
1565
Recruiting now
open to new participants
340
Lead sponsors
across recruiting studies
Top sites
Taipei 55 Kaohsiung City 30 Taichung 23 Taoyuan 22 Tainan 19

Trials in this register

69 of 2861 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Taiwan
Start
Recruiting
Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN
NCT07498335Berger Disease, Bergers Disease, IgA Nephropathy, Immunoglobulin A Nephropathy
Novartis Pharmaceuticals
Phase 3
28
Taipei, Taoyuan
2026-08-06
Recruiting
Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)
NCT07387926Acute Lymphoblastic Leukemia, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive, Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Novartis Pharmaceuticals
Phase 1/2
50
Taipei
2026-07-05
Recruiting
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
NCT07357727Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (PPV-MF), Post-essential Thrombocythemia Myelofibrosis (PET-MF)
Novartis Pharmaceuticals
Phase 3
460
Changhua, Kaohsiung City, Tainan, Taipei
2026-05-27
Active, closed
Novartis Pharmaceuticals
Phase 3
5,700
Taichung, Hsinchu, Kaohsiung City, Keelung, Tainan, Taipei, Taoyuan, Yilan
2026-05-11
Recruiting
A Study to Assess the Effects of Zigakibart on IgA Nephropathy.
NCT07146906Immunoglobulin A Nephropathy (IgAN)
Novartis Pharmaceuticals
Phase 2
32
Kaohsiung City, Taipei
2026-03-26
Recruiting
Novartis Pharmaceuticals
Phase 3
770
Changhua, Taipei, Taoyuan
2026-03-24
Recruiting
Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
NCT07288359Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Metastatic Castration-resistant Prostate Cancer
Novartis Pharmaceuticals
Phase 1/2
205
Taipei
2025-12-29
Recruiting
Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.
NCT06858319Kidney Diseases, Kidney Diseases, Chronic, Urological Diseases, Glomerulonephritis
Novartis Pharmaceuticals
Phase 3
220
Taipei
2025-07-28
Active, closed
Novartis Pharmaceuticals
Phase 2
168
Kaohsiung City, Tainan
2025-07-07
Active, closed
Novartis Pharmaceuticals
Phase 2
138
Taipei
2025-07-03
Recruiting
Novartis Pharmaceuticals
Phase 3
940
Kaohsiung City, Taichung, Tainan, Taipei, Taoyuan
2025-07-01
Recruiting
Novartis Pharmaceuticals
Phase 2
224
Kaohsiung City, Taipei
2025-05-16
Active, closed
Novartis Pharmaceuticals
Phase 3
246
Changhua, Kaohsiung City, Tainan, Taipei
2025-04-30
Recruiting
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
NCT06726148Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Extensive-stage Small Cell Lung Cancer
Novartis Pharmaceuticals
Phase 1/2
280
Tainan
2025-04-03
Recruiting
Novartis Pharmaceuticals
Phase 3
9
Taichung, Taipei
2025-02-28
Active, closed
Novartis Pharmaceuticals
Phase 3
180
Kaohsiung City, Tainan, Taipei, Taoyuan
2025-02-07
Active, closed
Novartis Pharmaceuticals
Phase 3
588
Kaohsiung City, Taipei, Taoyuan
2025-01-31
Active, closed
Phase 2 Study of Rapcabtagene Autoleucel in Myositis
NCT06665256Idiopathic Inflammatory Myopathies
Novartis Pharmaceuticals
Phase 2
21
Kaohsiung City, Taichung, Taipei
2024-12-17
Recruiting
Novartis Pharmaceuticals
Phase 3
60
Taipei
2024-12-09
Active, closed
Novartis Pharmaceuticals
Phase 2
96
Taichung
2024-10-29
Active, closed
Novartis Pharmaceuticals
Phase 2
203
Changhua, Kaohsiung City, Taichung, Taoyuan
2024-10-09
Active, closed
Novartis Pharmaceuticals
Phase 2
179
Taichung, Taipei
2024-09-04
Recruiting
Novartis Pharmaceuticals
Phase 3
550
Kaohsiung City, Taichung, Taipei, Taoyuan
2024-05-21
Recruiting
Novartis Pharmaceuticals
Phase 3
450
Taipei, Taoyuan
2024-03-12
Active, closed
Novartis Pharmaceuticals
Phase 3
1,466
Hualien City, Kaohsiung City, Tainan, Taipei
2024-02-28
Active, closed
Novartis Pharmaceuticals
Phase 3
109
Kaohsiung City, Taichung, Taipei
2023-10-02
Recruiting
Novartis Pharmaceuticals
Phase 3
106
Kaohsiung City
2023-10-02
Active, closed
A Study of Zigakibart in Adults With IgA Nephropathy
NCT05852938IgA Nephropathy, Immunoglobulin A Nephropathy
Novartis Pharmaceuticals
Phase 3
383
Keelung, Changhua County, Hsinchu, Hualien City, Kaohsiung City, Tainan, Taipei
2023-07-06
Active, closed
Novartis Pharmaceuticals
Phase 1
123
Taipei
2023-06-27
Active, closed
Novartis Pharmaceuticals
Phase 3
288
Kaohsiung City, Taichung, Taipei, Taoyuan
2023-04-21
Active, closed
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
NCT05739383Primary Prevention of Atherosclerotic Cardiovascular Disease
Novartis Pharmaceuticals
Phase 3
14,012
Taichung, Changhua, Kaohsiung City, Tainan, Taipei, Taoyuan
2023-03-09
Recruiting
Novartis Pharmaceuticals
Phase 3
195
Taipei
2023-02-10
Active, closed
Novartis Pharmaceuticals
Phase 3
152
Taoyuan
2023-02-02
Active, closed
Novartis Pharmaceuticals
Phase 3
20
Kaohsiung City, Taipei
2022-12-19
Active, closed
Novartis Pharmaceuticals
Phase 3
696
Taichung, Taipei, Taoyuan
2022-12-09
Active, closed
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
NCT05544929Carcinoma, Non-Small-Cell Lung, Cutaneous Melanoma, Carcinoma, Renal Cell, Carcinoma, Ovarian Epithelial
Novartis Pharmaceuticals
Phase 1
126
Taipei
2022-10-26
Recruiting
Asciminib Roll-over Study
NCT04877522Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Novartis Pharmaceuticals
Phase 4
347
Taoyuan
2022-08-30
Active, closed
Novartis Pharmaceuticals
Phase 3
506
Kaohsiung City, Taichung
2022-08-04
Active, closed
Novartis Pharmaceuticals
Phase 3
452
Kaohsiung City, Taichung, Taipei
2022-07-14
Active, closed
Novartis Pharmaceuticals
Phase 4
134
Taipei
2022-07-07
Active, closed
Novartis Pharmaceuticals
Phase 3
1,000
Kaohsiung City, Tainan, Taipei, Taoyuan
2021-12-16
Active, closed
Novartis Pharmaceuticals
Phase 3
17,004
Kaohsiung City, Tainan, Taipei
2021-11-23
Active, closed
A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
NCT04971226Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive
Novartis Pharmaceuticals
Phase 3
405
Taichung
2021-10-06
Active, closed
Novartis Pharmaceuticals
Phase 3
129
Tainan, Taipei
2021-10-05
Recruiting
Novartis Pharmaceuticals
Phase 3
540
Kaohsiung City, New Taipei City, Taichung, Taipei, Taoyuan
2021-09-20
Active, closed
Novartis Pharmaceuticals
Phase 3
208
Hualien City, Taipei
2021-07-27
Active, closed
Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)
NCT04603495Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
Novartis Pharmaceuticals
Phase 3
430
Chiayi City, Taichung, Taipei
2021-04-09
Active, closed
Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
NCT04699188KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small-Cell Lung, Carcinoma, Colorectal, Cancer of Lung
Novartis Pharmaceuticals
Phase 1/2
344
Taipei
2021-02-24
Active, closed
Atrasentan in Patients With IgA Nephropathy
NCT04573478IgA Nephropathy, Immunoglobulin A Nephropathy
Novartis Pharmaceuticals
Phase 3
404
Changhua, Hsinchu, New Taipei City, Taipei
2020-12-11
Active, closed
Novartis Pharmaceuticals
Phase 4
14
Kaohsiung City, Taichung, Taipei
2020-10-12
Active, closed
Novartis Pharmaceuticals
Phase 1
120
Taipei
2019-10-30
Active, closed
Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors.
NCT03891953Carcinoma, Non-Small-Cell Lung, Melanoma, Nasopharyngeal Carcinoma, Microsatellite Stable Colorectal Cancer
Novartis Pharmaceuticals
Phase 1
98
Taipei
2019-05-07
Active, closed
Novartis Pharmaceuticals
Phase 3
5,101
Changhua, Taichung, Tainan, Taipei, Taoyuan
2018-12-07
Recruiting
Novartis Pharmaceuticals
Observational
700
Kaohsiung City, Taichung, Taipei, Taoyuan
2018-09-25
Active, closed
Novartis Pharmaceuticals
Phase 1
105
Tainan, Taipei
2018-01-29
Active, closed
Ribociclib (LEE011) Rollover Study for Continued Access
NCT02934568Continued Access to Study Treatment(s), Cancers With a Mass, Bulky Tumor, Nodule, Lump, Advanced Cancer, Advanced Solid Tumors, Advanced Solid Malignancies
Novartis Pharmaceuticals
Phase 2
22
Tainan, Taipei
2016-12-15
Active, closed
Novartis Pharmaceuticals
Phase 4
233
Taichung, Taipei, Taoyuan
2015-12-11
Recruiting
CAR-T Long Term Follow Up (LTFU) Study
NCT02445222Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program
Novartis Pharmaceuticals
Phase 3
1,105
Taipei
2015-11-02
Rows per page Showing 1–69 of 69
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Taiwanese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 18 November 2026. https://priyalifescience.com/clinical-trials-taiwan

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Taiwan and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,861 studies in total at the last sync on 15 Nov 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 69 of those studies that match the filters currently applied.

How many clinical trials are recruiting in Taiwan?

24 of the 69 studies on this page are recruiting new participants as of the 15 Nov 2026, 03:18 UTC sync. A further 0 have not yet opened recruitment, 45 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase, 69 studies
PhaseStudiesRecruitingShare
Phase 3451665.2%
Phase 29213%
Phase 1507.2%
Phase 1/2435.8%
Phase 4415.8%
Observational111.4%
Phase 2/3111.4%

Most active sponsors

Lead sponsors with the most studies
Lead sponsorStudiesRecruiting
Novartis Pharmaceuticals6924

This register, in your inbox every Friday

One email a week with how many trials are recruiting in Ireland, new EMA and FDA approvals and medicine shortages, built from the same public registers as this page.

Free. Unsubscribe from any email with one click. See our privacy policy.

→

Browse trials by condition

IgA Nephropathy (3) Immunoglobulin A Nephropathy (3) Lupus Nephritis (3) Carcinoma, Non-Small-Cell Lung (3) Prostate Cancer (2) Relapsing Multiple Sclerosis (2) Early Breast Cancer (2) Systemic Lupus Erythematosus (2) Advanced HR+/HER2- Breast Cancer (2) Advanced CCNE1-amplified Solid Tumors (2) Chronic Spontaneous Urticaria (2) Spinal Muscular Atrophy (SMA) (2) Sjogren Syndrome (1) MSIhi or dMMR Advanced Unresectable or Metastatic Solid Tumors, Including Colorectal Cancers (1) Acute Lymphoblastic Leukemia (1)
→

Browse trials by site location

Taipei (55) Kaohsiung City (30) Taichung (23) Taoyuan (22) Tainan (19) Changhua (7) Hsinchu (4) Hualien City (3) Keelung (2) New Taipei City (2) Changhua County (1) Chiayi City (1) Yilan (1)
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.